Pain News and Research

Latest Pain News and Research

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.

27 Jun 2013

Anesthesia & Analgesia journal of IARS achieves another increase in its "Impact Factor"

The International Anesthesia Research Society (IARS) is pleased to announce that Anesthesia & Analgesia, official journal of the IARS, has achieved yet another increase in its "Impact Factor"—a key indicator of the influence and scientific value of medical journals.

26 Jun 2013

Physician’s unfavorable attitudes about opioid drugs linked with lower rates of prescribing

According to a study of physicians' attitudes about pain drugs published in The Journal of Pain, negative physician attitudes about opioid medications are closely associated with lower rates of prescribing and more favorable attitudes are linked with higher prescribing levels.

26 Jun 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Study explores analgesic activity of ceftriaxone in humans

A single dose of the antibiotic ceftriaxone given for antimicrobial prophylaxis prior to surgery enhanced patient pain thresholds after the procedure, according to a study published in The Journal of Pain, the peer review publication of the American Pain Society.

26 Jun 2013

Primary care physicians prefer to prescribe NSAIDS for chronic pain, report shows

For treating the estimated 100 million Americans with chronic pain -- a population larger than those with heart disease, cancer and diabetes combined -- researched reported in The Journal of Pain shows that primary care physicians overwhelmingly prefer to prescribe non-steroidal anti-inflammatory medications, in accordance with published clinical practice guidelines.

26 Jun 2013

First Edition: June 25, 2013

Today's headlines include reports about the Obama administraiton's plans for getting the word about the health law's online marketplaces.

25 Jun 2013

In effort to reduce veterans' suicide rate, officials seek to deal with 'moral injury'

An estimated 22 veterans kill themselves in the U.S. each day. And suicide among men and women on active duty hit a record high last year -- 349. As veterans and researchers try to figure out why, there's growing interest in a condition known as "moral injury," or wounds to a veteran's spirit or soul from events that "transgress deeply held moral beliefs and expectations."

25 Jun 2013

State highlights: Calif. eyes health care for immigrants; New scrutiny for N.Y. home health firms; Examining Ore. insurers' choice on smokers

When Congress passed President Obama's health care overhaul, a critical compromise provision was that immigrants living in the United States illegally would not be allowed access to publicly subsidized health insurance.

25 Jun 2013

Viewpoints: Mich. gov. says Medicaid expansion would save money, lives; CMS on making medical devices affordable

The people of Michigan elected the members of the state Senate to be leaders, not vacationers. Unfortunately, the Senate forgot that Thursday and adjourned for its summer vacation. It left Lansing without voting on a bill that would provide health care coverage to nearly half a million working Michiganders. Ensuring access to affordable, quality health care is one of the most significant challenges facing Michigan. The Healthy Michigan plan developed over the past several months is a plan that addresses many of the state's needs and reflects the state's values (Gov. Rick Snyder, 6/23).

25 Jun 2013

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of RBX2660 (microbiota suspension), intended for the treatment of recurrent Clostridium difficile infection.

25 Jun 2013

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.

25 Jun 2013

New method allows assessment of direct stimulation effects on electric activity of human brain

Neuroscientists at the University of Tübingen have become the first to record neuromagnetic activity in the millisecond-by-millisecond range while the brain of a human subject was under stimulation by electric current. Electric brain stimulation has successfully been used in the treatment of neurological and psychiatric disorders for many decades.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

Young people need to wise up and turn the volume down on their earbuds, says audiologist

In today's disposable society, hearing is an endangered species. "Once hearing is damaged, it cannot be repaired," said Jyoti Bhayani, a certified audiologist at Gottlieb Memorial Hospital, part of Loyola University Health System. "And hearing aids have yet to become coveted status accessories so young people need to wise up and turn the volume down on their earbuds."

21 Jun 2013

Residents in anesthesiology training programs have high rates of burnout and depression

Residents in anesthesiology training programs have high rates of burnout and depression, reports a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

21 Jun 2013

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Today, the U.S. Food and Drug Administration announced it has approved the use of Plan B One-Step (levonorgestrel) as a nonprescription product for all women of child-bearing potential.

21 Jun 2013

Researchers launch clinical trial on stem cells to prevent amputations in end stage PAD

University Hospitals Case Medical Center clinical researchers have launched an innovative clinical trial, unique in its design, which will evaluate the ability of a patient's own stem cells to prevent leg amputations in end stage peripheral arterial disease (PAD).

20 Jun 2013

FDA accepts DURECT's New Drug Application for POSIDUR

DURECT Corporation today announced that the New Drug Application for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration indicating that the application is sufficiently complete to permit a substantive review.

20 Jun 2013

Pain News and Research

Latest Pain News and Research

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

Anesthesia & Analgesia journal of IARS achieves another increase in its "Impact Factor"

Physician’s unfavorable attitudes about opioid drugs linked with lower rates of prescribing

Eisai submits BELVIQ NDS with Health Canada

Study explores analgesic activity of ceftriaxone in humans

Primary care physicians prefer to prescribe NSAIDS for chronic pain, report shows

First Edition: June 25, 2013

In effort to reduce veterans' suicide rate, officials seek to deal with 'moral injury'

State highlights: Calif. eyes health care for immigrants; New scrutiny for N.Y. home health firms; Examining Ore. insurers' choice on smokers

Viewpoints: Mich. gov. says Medicaid expansion would save money, lives; CMS on making medical devices affordable

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

New method allows assessment of direct stimulation effects on electric activity of human brain

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Young people need to wise up and turn the volume down on their earbuds, says audiologist

Residents in anesthesiology training programs have high rates of burnout and depression

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Researchers launch clinical trial on stem cells to prevent amputations in end stage PAD

FDA accepts DURECT's New Drug Application for POSIDUR

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Pain News and Research

Latest Pain News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in